SMS Pharmaceuticals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹316 Cr +30.6% YoYSee revenue, profit and what management said. You are viewing Q1 FY26.
SP

SMS Pharmaceuticals Ltd

Q1 FY26Pharmaceuticals & Biotechnology

SMS Pharmaceuticals Q1 FY26: Revenue ₹196.05 Cr, PAT ₹20.50 Cr

Q1 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹196Cr
+19.5% YoY
−21% QoQ
Net profit
₹20Cr
+25% YoY
0% QoQ
Margin
20%
0 pp YoY
+4 pp QoQ

Based on SMS Pharmaceuticals Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹474
Market cap₹4.1K Cr
P/E40.5

The short version

Q1FY26 revenue from operations: ₹196.05 crore - Year-on-year (YoY) revenue growth: 19% (Q1FY26 vs Q1FY25) - Quarterly revenue trend: from ₹164.45 crore in Q1FY25 to ₹196.05 crore in Q1FY26 - Vol EBITDA for Q1FY26: ₹39.37 crore, up 17% YoY - EBITDA Margin: 20%, stable YoY (Q1FY26 vs Q1FY25) - Profit After Tax (PAT) for Q1FY26: ₹20.50 crore (after minority interest and associate s

From SMS Pharmaceuticals Ltd's Q1 FY26 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Q1FY26 revenue from operations: ₹196.05 crore
  • Year-on-year (YoY) revenue growth: 19% (Q1FY26 vs Q1FY25)
  • Quarterly revenue trend: from ₹164.45 crore in Q1FY25 to ₹196.05 crore in Q1FY26

2 more points from SMS Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what SMS Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • New Capex plan of ₹250 crore approved for existing and new products, R&D facility, and CMO business (Page 16).
  • Capacity expansion aiming to achieve a production target of 1,000 MT per month (Page 16).
  • Started commercial production of key intermediates; gross margin impact expected in Q2FY26 (Page 4).
  • ₹250 crore Capex plan is on track as of Q1FY26 (Page 4).

2 more points from SMS Pharmaceuticals Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what SMS Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what SMS Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.

SMS Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

SMS Pharmaceuticals Ltd Q1 FY26 results — key figures

SMS Pharmaceuticals Ltd Q1 FY26 reported results vs Q1 FY25, ₹ crore
₹ CrQ1 FY26Q1 FY25YoYQ4 FY25QoQ
Revenue196164+19.5%248-21%
Operating profit (EBITDA)3934+14.7%41-4.9%
Operating margin20%20%0 pp16%+4 pp
Profit before tax2422+9.1%29-17.2%
Net profit (PAT)2016+25%200%
EPS (₹)2.311.95+18.5%2.29+0.9%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹316 Cr, net profit ₹40 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • RPG Life Sciences (Q1 FY26)

    168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • Morepen Laboratories (Q1 FY26)

    Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • NGL Fine Chem (Q1 FY26)

    Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • Influx Healthtech (Q1 FY26)

    FY25 revenue from operations: ₹104.9 crores, up 5% YoY from ₹99.9 crores in FY24 (Page 28 & 26). Key concall takeaways from Influx Healthtech Ltd's Q1 FY26…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

SMS Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were SMS Pharmaceuticals Ltd Q1 FY26 results?

Q1FY26 revenue from operations: ₹196.05 crore - Year-on-year (YoY) revenue growth: 19% (Q1FY26 vs Q1FY25) - Quarterly revenue trend: from ₹164.45 crore in Q1FY25 to ₹196.05 crore in Q1FY26 - Vol EBITDA for Q1FY26: ₹39.37 crore, up 17% YoY - EBITDA Margin: 20%, stable YoY (Q1FY26 vs Q1FY25) - Profit After Tax (PAT) for Q1FY26: ₹20.50 crore (after minority interest and associate s

What is SMS Pharmaceuticals Ltd share price analysis?

SMS Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 40.5 with a market cap of ₹4,148 Cr. Investors should review the full earnings analysis for detailed insights.

Is SMS Pharmaceuticals Ltd planning capital expenditure?

New Capex plan of ₹250 crore approved for existing and new products, R&D facility, and CMO business (Page 16).

Keep SMS Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.